Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10720509 | 0.88 | L3MBTL1 (0.71) | HPGDKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL7130857 | 0.88 | HPGD (0.83) | HPGDKDM4EL3MBTL1HTTALDH1A1 | |
| SCHEMBL14238822 | 0.88 | HPGD (0.83) | HPGDKDM4EL3MBTL1HTTALDH1A1 | |
| SCHEMBL1753626 | 0.85 | HPGD (0.97) | HPGDMEN1KMT2AL3MBTL1HTT | |
| SCHEMBL2667152 | 0.85 | HPGD (0.90) | HPGDKDM4EL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL28611993 | 0.84 | LMNA (0.59) | HPGDKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL10174633 | 0.83 | HPGD (1.00) | HPGDMEN1KMT2AL3MBTL1LMNA | |
| SCHEMBL12969 | 0.83 | HPGD (1.00) | HPGDMEN1KMT2AL3MBTL1LMNA | |
| SCHEMBL28294867 | 0.83 | HPGD (0.71) | HPGDKDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6465429 | 0.83 | HPGD (0.68) | HPGDKDM4EL3MBTL1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| EP-3820849-B1 | PHENYL/PYRIDYL-NH-PHENYL/PYRIDYL DERIVATIVES FOR TREATING RNA VIRUS INFECTION | ABIVAX (FR) | 2023-09-06 | — | — | EP | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11664093-B2 | Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2023073115-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| WO-2007075468-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
| US-4988822-A | Intermediates for preparing 5-aroyl-1,2-dihydro-3H-pyrrolo(1,2-A)pyrrole-1,1-dicarboxylates | SYNTEX (U.S.A.) INC. (US) | 1991-01-29 | — | — | US | disclosed |
| US-4873340-A | Process for preparing 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-A]pyrrole-1,1-dicarboxylates | SYNTEX (U.S.A.) INC. (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0053021-B1 | PROCESS FOR 5-AROYLATION OF 1,2-DIHYDRO-3H-PYRROLO(1,2-A)PYRROLE-1-CARBOXYLIC ESTERS AND NITRILES | SYNTEX (U.S.A.) INC. (US) | 1985-05-02 | — | — | EP | disclosed |
| US-4353829-A | AROYL MORPHOLIDE REAGENT | SYNTEX (U.S.A.) INC. (US) | 1982-10-12 | — | — | US | disclosed |
| EP-0053021-A2 | Process for 5-aroylation of 1,2-dihydro-3H-pyrrolo(1,2-a)pyrrole-1-carboxylic esters and nitriles | SYNTEX (U.S.A.) INC. (US) | 1982-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | HPGD 4752/4885KDM4E 395/4885MEN1 3978/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | HPGD 140/4885KDM4E 2437/4885MEN1 629/4885 |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | HPGD 1498/4885KDM4E 1491/4885MEN1 1462/4885 |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | IL2, IRF3, EIF2AK2 | HPGD 449/4885KDM4E 3178/4885MEN1 4622/4885 |
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | IFNG, IRF3, IDO1 | HPGD 27/4885KDM4E 1279/4885MEN1 3889/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | HPGD 1641/4885KDM4E 3690/4885MEN1 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.